Alzamend Neuro eliminates Series B and Series C convertible preferred stock

Alzamend Neuro, Inc.

Filed Certificates of Elimination for Series B and Series C convertible preferred stock with Delaware Secretary of State on October 14, 2025.
The elimination removes all matters set forth in the Certificates of Designations for those preferred stock series from the company's charter.
No other changes to the capital structure, financial terms, or stock trading were disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Filed Certificates of Elimination to remove Series B and Series C preferred stock designations from the Certificate of Incorporation (effective 2025-10-14).

Change: charter amendment
Effective: 2025-10-14

Exact text from the filing

On October 14, 2025, Alzamend Neuro , Inc., a Delaware corporation (the “ Company ”), filed Certificates of Elimination (collectively, the “ Certificates of Elimination ”) with the Secretary of State of the State of Delaware with respect to the Company’s Series B convertible preferred stock and Series C convertible preferred stock (collectively, the “ Preferred Stock ”), which, effective upon filing, eliminated from the Company’s Certificate of Incorporation, as amended, all matters set forth in the Certificates of Designations for the Preferred Stock.

View on SEC.gov

Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-014950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.